grant
CD200R blockade for cancer immunotherapy
Organization OHIO STATE UNIVERSITYLocation Columbus, UNITED STATESPosted 1 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025AddressAdoptive TransferAdvanced CancerAdvanced Malignant NeoplasmAffinityAngiogenesis AntagonistsAngiogenesis BlockersAngiogenesis InhibitionAngiogenesis InhibitorsAngiogenetic AntagonistsAngiogenetic InhibitorsAngiogenic AntagonistsAngiogenic InhibitionAngiogenic InhibitorsAngiostatic AgentsAnti-Angiogenetic AgentsAnti-Angiogenic AgentsAnti-Angiogenic DrugsAntiangiogenesis AgentsAntiangiogenic AgentsAntiangiogenic DrugsAntibodiesB220Basal Transcription FactorBasal transcription factor genesBlood EosinophilBlood NeutrophilBlood Polymorphonuclear NeutrophilCCL24CCL24 geneCCL3CCL3 geneCCL8CCL8 geneCD 200CD200CD45CD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCINC-2CINC-2bCXCL2CXCL2 geneCXCL3CXCL3 geneCancer TreatmentCancersCell BodyCell Communication and SignalingCell DeathCell FunctionCell PhysiologyCell ProcessCell SignalingCellsCellular FunctionCellular PhysiologyCellular ProcessCheckpoint inhibitorChemokine (C-C motif) Ligand 3Chemokine, CXC Motif, Ligand 2Chemotactic CytokinesCkb-6Clinical TrialsCombined Modality TherapyDevelopmentDown-RegulationEosinophilic GranulocyteEosinophilic LeukocyteExhibitsG0S19-1GP180GRO Protein, BetaGRO2GRO2 OncogeneGRO3GRObGROgGROβGene ModifiedGeneral Transcription Factor GeneGeneral Transcription FactorsGeneticGoalsHC14Homologous Chemotactic CytokinesHumanImmuneImmune TargetingImmune checkpoint inhibitorImmune infiltratesImmune mediated therapyImmunesImmunologic ReceptorsImmunological ReceptorsImmunologically Directed TherapyImmunotherapyInfiltrationIntercrinesIntracellular Communication and SignalingKI miceKnock-inKnock-in MouseLD78ALPHALY5LYT3LymphoidMCP-2MCP2MIP 1alphaMIP-1-alphaMIP-1aMIP-2AMIP-2BMIP1AMIP2-alphaMIP2AMIP2BMIP2αMPIF-2MPIF2MacrophageMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMarrow EosinophilMarrow NeutrophilMediatingMiceMice MammalsModern ManMultimodal TherapyMultimodal TreatmentMurineMusMyelogenousMyeloidMyeloid CellsMφNeovascularization InhibitorsNeutrophil InfiltrationNeutrophil RecruitmentNeutrophilic GranulocyteNeutrophilic InfiltrateNeutrophilic LeukocytePTPRCPTPRC genePathogenesisPathway interactionsPatientsPhenotypePolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsRoleSCYA10SCYA24SCYA3SCYA8SCYB2SCYB3SIS cytokinesSignal TransductionSignal Transduction SystemsSignalingSmall Inducible Cytokine A3Small Inducible Cytokine Subfamily B, Member 2Stem Cell InhibitorSubcellular ProcessT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyT200T8 CellsT8 LymphocytesTeff cellTestingTherapeutic antibodiesTranscription Factor Proto-OncogeneTranscription factor genesTransgenic OrganismsTumor AngiogenesisTumor AntigensTumor CellTumor PromotionTumor-Associated AntigenUpregulationVascularizationWorkXBP1XBP1 geneadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyangiogenesisantagonismantagonistanti-cancer immunotherapyanti-cancer therapyantiangiogenicanticancer immunotherapyantigen-specific T cellsbiological signal transductioncancer antigenscancer immunotherapycancer infiltrating T cellscancer microenvironmentcancer therapycancer-directed therapycell typecheck point blockadecheckpoint blockadechemoattractant cytokinechemokinecombination therapycombined modality treatmentcombined treatmentdevelopmentaleffector T cellefficacy testingeosinophilgene modificationgenetically modifiedimmune cell infiltrateimmune check pointimmune check point blockadeimmune check point inhibitorimmune checkpointimmune checkpoint blockadeimmune receptorimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmunecheckpointimmuno therapyimmunotherapy for cancerimmunotherapy of cancerimprovedin vivoknockinknockin micemacrophage inflammatory protein 2malignancymouse modelmulti-modal therapymulti-modal treatmentmurine modelnecrocytosisneoplasm/cancerneoplastic cellneutrophilnovelpathwayrecruitrestraintsocial rolesynergismtherapeutic T-cell platformthymus derived lymphocytetraffickingtranscription factortransgenictumortumor growthtumor infiltrating T cellstumor microenvironmenttumor-specific antigenβ-GRO protein
Description preview
PROJECT SUMMARY
Immunotherapies based on the blockade of immune checkpoints have revolutionized cancer treatment in recent
years. Today, immune checkpoint inhibitors in development aim to reactivate tumor-infiltrating T cells to facilitate
tumor cell death. In many tumor types, however, the most abundant form of infiltrating immune cells are…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click